At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 89 enrolled
Drug / intervention
LT3001 Drug Product +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS)
In Brief
A Phase 2 clinical trial evaluating LT3001 Drug Product and Placebo for Acute Ischemic Stroke. Completed, enrolled 89 participants across 1 site.
Detailed Summary
This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartAug 2022
Primary CompletionMay 2025
TodayJul 2026
First PostedJun 3, 2022
Enrollment StartAug 17, 2022
Primary CompletionMay 23, 2025
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 4.1 years ago
Interventions
LT3001 Drug Productdrug
Administered by intravenous infusion
Placebodrug
Administered by intravenous infusion